# **ARTICLE IN REVIEW:**

# HuBiogel<sup>™</sup>-based 3D microtumor model for high-throughput drug screening

#### PUBLICATION: Scientific Reports, May 2018

**TITLE:** Combinatorial Drug Testing in 3D Microtumors Derived From GBM Patient-Derived Xenografts Reveals Cytotoxic Synergy in Pharmacokinomics-informed Pathway Interactions<sup>1</sup>

**AUTHORS:** Gilbert AN, Anderson JC, Duarte CW, Shevin RS, Langford CP, Singh R, Gillespie GY, Willey CD

#### STUDY DESIGN: Benchtop

**SUMMARY:** Currently, drug safety and efficacy, chemical toxicity, and other important types of testing are performed in either animal models or two-dimensional (2D) cell cultures. However, these methods often fail to accurately represent the human in vivo environment and may lead to ineffective therapies. Patient-derived xenografts (PDX), in which patient-derived tumors are grown in immunocompromised mice, have offered attractive cancer models for human tumor representation; however, they lack the ability for high-throughput drug testing. This paper reports the use of a fully human-derived HuBiogel extracellular matrix (ECM) to develop a three-dimensional (3D) microtumor model of glioblastoma mutliforme (GBM) PDX tumor cells, which mimics the human microenvironment. GBM microtumors closely resembled murine-implanted tumors and displayed global kinase (kinomic) and morphological diversity. Drug response screening could be reproducibly performed in a 96-well format using 4 small molecules, singularly and in combination. Therefore, the fully human-derived HuBiogel-based 3D microtumor model is effective for high-throughput combinatorial drug screening in order to evaluate therapeutic effectiveness.

#### **Reference**:

 Gilbert AN, Anderson JC, Duarte CW, et al. Combinatorial Drug Testing in 3D Microtumors Derived from GBM Patient-Derived Xenografts Reveals Cytotoxic Synergy in Pharmacokinomics-informed Pathway Interactions. Sci Rep. 2018;8(1):8412. doi:10.1038/s41598-018-26840-4

68-20-321.00

LifeNet Health and the LifeNet Health logo are registered trademarks of LifeNet Health. HuBiogel is a trademark of LifeNet Health. ©2021 LifeNet Health, Virginia Beach, VA. All rights reserved.

## Preservation of native tumor physiology:

3D microtumors grown in HuBiogel maintained their native proliferative capacity and morphological characteristics (colony-like formation and invasive properties) similar to murine-implanted tumors.

# Biological diversity of 3D microtumors:

3D microtumors exhibited reproducible kinomic diversity. The HuBiogel ECM allowed signaling of the embedded tumor cells.

# Effective model for high-throughput drug screening:

Individual and combinatorial high-throughput drug screening was reproducibly performed on the 3D microtumors grown in HuBiogel.

### GBM PDX cells form 3D microtumors in HuBiogel



Figure 2A. Reproduced with permission under an open access license.<sup>1</sup>

